Subtype
Malignant Intestinal Neoplasm
CI-CAN-00001137Explore in graph →
1,666 active trials21 approved drugs383 evidence items
- NCIt
- C4572
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001137Explore in graph →
Clinical trials
7,773 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (772)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02402842 | Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma(Epitopes-HPV02) | completed | Phase 2 | 70 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT04561336 | Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer | completed | Phase 2 | 77 | University of Campania Luigi VanvitelliOTHER | 1 | May 5, 2022 |
| clinicaltrials |
| NCT03666442 | Early Evaluation of Chemosensitivity for Low/Intermediated-risk Mid-low Stage II/III Rectal Cancer | completed | Phase 2 | 61 | West China HospitalOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT01516216 | Study of Vitamin D in Untreated Metastatic Colorectal Cancer | completed | Phase 2 | 139 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT03102047 | Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer | completed | Phase 2 | 45 | NSABP Foundation IncNETWORK | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03799731 | Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers | completed | Phase 2 | 65 | GamaMabs PharmaINDUSTRY | 2 | Apr 14, 2022 | clinicaltrials |
| NCT04425239 | Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer(IMPROVE) | completed | Phase 2 | 151 | National Cancer Institute, NaplesOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT05316818 | Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma | completed | Phase 2 | 64 | Kasr El Aini HospitalOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT03832621 | NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer(MAYA) | completed | Phase 2 | 135 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT02439385 | Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis | completed | Phase 2 | 44 | Gachon University Gil Medical CenterOTHER | 0 | Mar 31, 2022 | clinicaltrials |
| NCT02404935 | Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)(TIME) | completed | Phase 2 | 139 | UNICANCEROTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT03000374 | Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery(PIER) | completed | Phase 2 | 34 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT04247984 | A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer | completed | Phase 2 | 264 | Chinese Academy of Medical SciencesOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT05274945 | Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer | completed | Phase 2 | 58 | Alexandria UniversityOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT03254394 | Lidocaine for Oxaliplatin-induced Neuropathy | completed | Phase 1 / Phase 2 | 26 | Washington University School of MedicineOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT03359681 | Metformin Treatment for Colon Cancer(MECORA) | completed | Phase 2 | 48 | Zealand University HospitalOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT03454620 | A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy | completed | Phase 1 / Phase 2 | 53 | Green Cross CorporationINDUSTRY | 1 | Mar 3, 2022 | clinicaltrials |
| NCT03403634 | Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver | completed | Phase 2 | 19 | Roswell Park Cancer InstituteOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT02375672 | Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer | completed | Phase 2 | 30 | Hoosier Cancer Research NetworkOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02292758 | Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 36 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT00193219 | Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 36 | SCRI Development Innovations, LLCOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT00308516 | 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer | completed | Phase 2 | 66 | SCRI Development Innovations, LLCOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT00803647 | A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver | completed | Phase 2 | 20 | NSABP Foundation IncNETWORK | 1 | Oct 6, 2021 | clinicaltrials |
| NCT01535040 | Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking | completed | Phase 2 | 130 | Wake Forest University Health SciencesOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT03803241 | Cd133+ Cell Infusion in Patients With Colorectal Liver Metastases.(cellcol) | completed | Phase 2 | 4 | Hospital San Carlos, MadridOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT00640081 | Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer | completed | Phase 2 | 169 | Cheryl PughOTHER_GOV | 2 | Sep 22, 2021 | clinicaltrials |
| NCT00655499 | Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer(PIMABI) | completed | Phase 2 | 65 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Sep 21, 2021 | clinicaltrials |
| NCT01006369 | Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 38 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 21, 2021 | clinicaltrials |
| NCT03261947 | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors | completed | Phase 2 | 101 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 20, 2021 | clinicaltrials |
| NCT00007943 | Gemcitabine in Treating Patients With Advanced Colorectal Cancer | completed | Phase 2 | 15 | Wake Forest University Health SciencesOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT02414009 | Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients(CAPTEM) | completed | Phase 2 | 82 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT03564912 | Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC | completed | Phase 1 / Phase 2 | 160 | Zhejiang UniversityOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT00040599 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | completed | Phase 1 / Phase 2 | 72 | Gilead SciencesINDUSTRY | 5 | Aug 19, 2021 | clinicaltrials |
| NCT00041652 | Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer | completed | Phase 1 / Phase 2 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT00574678 | Analyzing the Composition of Tears to Identify Cancer(ACT) | completed | Phase 1 / Phase 2 | 150 | University of ArkansasOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT02864849 | Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer | completed | Phase 2 | 81 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jul 23, 2021 | clinicaltrials |
| NCT00844233 | Study of Chemoembolisation Using Irinotecan Bead Prior to Surgery in Metastatic Colorectal Cancer(PARAGON-II) | completed | Phase 1 / Phase 2 | 40 | Boston Scientific CorporationINDUSTRY | 3 | Jul 21, 2021 | clinicaltrials |
| NCT00598975 | NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b) | completed | Phase 2 | 18 | Nektar TherapeuticsINDUSTRY | 1 | Jul 12, 2021 | clinicaltrials |
| NCT00856375 | NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer | completed | Phase 2 | 83 | Nektar TherapeuticsINDUSTRY | 6 | Jul 12, 2021 | clinicaltrials |
| NCT02393755 | Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT01276379 | Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab(POSIBA) | completed | Phase 2 | 221 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | Jul 2, 2021 | clinicaltrials |
| NCT01719380 | Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | completed | Phase 2 | 156 | PfizerINDUSTRY | 12 | Jun 23, 2021 | clinicaltrials |
| NCT01902953 | Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC) | completed | Phase 2 | 16 | Maimonides Medical CenterOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT03142516 | FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status(OPALO) | completed | Phase 2 | 20 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT01442935 | Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases | completed | Phase 2 | 256 | UNICANCEROTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT02227667 | Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer | completed | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT02181556 | Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 41 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jun 7, 2021 | clinicaltrials |
| NCT03427268 | Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment | completed | Phase 2 | 32 | PharmaMarINDUSTRY | 3 | May 24, 2021 | clinicaltrials |
Data updated 23 days agoSource updated May 16, 2022source: clinicaltrials